| Not Yet Recruiting | Fianlimab&Cemiplimab as TotalNeoadj The (TNT) ForMelanoma NCT07527325 | University of California, Irvine | Phase 2 |
| Recruiting | A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HM NCT06956690 | Hummingbird Bioscience | Phase 1 / Phase 2 |
| Recruiting | Omitting Therapeutic Lymph Node Dissection in Patients With Melanoma (Stage 3) and Major Pathological Response NCT06754904 | D.J. (Dirk) Grünhagen | N/A |
| Recruiting | Evaluation of a Personalised Survivorship Care Plan App for Patients With Melanoma NCT06643286 | Erasmus Medical Center | N/A |
| Active Not Recruiting | One-year Recurrence-free Survival of Melanoma Patients Eligible for a Sentinel Lymph Node Biopsy NCT06809491 | Central Hospital, Nancy, France | — |
| Recruiting | Real-life Pharmacological Monitoring of Encorafenib-Binimetinib in the Treatment of Metastatic Melanoma NCT06774989 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma NCT06771544 | University of California, Irvine | Phase 2 |
| Recruiting | DermaSensor Postmarket Surveillance Study NCT06666790 | DermaSensor, Inc. | N/A |
| Completed | Head and Neck Melanoma; Access to Staging and Surgical Treatment NCT05900102 | Hull University Teaching Hospitals NHS Trust | — |
| Recruiting | Observational Study of Patients With Advanced Melanoma (Skin Cancer) to Assess if IOpener®-Melanoma Test Can P NCT06784778 | Pamgene International B.V. | — |
| Recruiting | High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial NCT06298734 | Fred Hutchinson Cancer Center | N/A |
| Recruiting | A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma NCT06377111 | University Health Network, Toronto | Phase 1 |
| Recruiting | Rural Adult and Youth Sun Protection Study NCT06439979 | University of Utah | N/A |
| Active Not Recruiting | Clinical Study of the Efficacy and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Mela NCT06640530 | Biocad | Phase 3 |
| Unknown | Leaderboard Influence on Self-Regulated Training in a Gamified Dermoscopy Training App NCT06254547 | Herlev Hospital | N/A |
| Recruiting | Understanding the Transition from Normal Melanocytes to Nevus to Melanoma NCT06605417 | Fundacion Clinic per a la Recerca Biomédica | — |
| Completed | Safety and Avoidance of Futile Excisions Through Skin Tele-triage NCT05982600 | Herlev Hospital | — |
| Unknown | Effect of Topical Application of Hypertonic Saline on Melanoma on Its Sizes and Number. NCT05854589 | Rafik Batroussy | Phase 2 |
| Enrolling By Invitation | Dermoscopy Augmented Histology Trial, Consensus Agreement Diagnosis Made by Dermatopathology Experts NCT05712551 | Herlev Hospital | — |
| Active Not Recruiting | A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Sk NCT05751928 | Biocad | Phase 3 |
| Unknown | LifeChamps Feasibility Study NCT05990634 | Region Stockholm | N/A |
| Recruiting | Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases NCT05704647 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer NCT05492682 | Valo Therapeutics Oy | Phase 1 |
| Completed | Mentored Community Gardening for Individuals With Skin Cancer NCT05648604 | University of Arizona | N/A |
| Recruiting | Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint Inhibi NCT05649683 | Centre Hospitalier Universitaire de Nice | N/A |
| Unknown | MR Lymphography and Magnetic Sentinel Lymph Node Biopsy in Melanoma Patients NCT05569707 | University of Twente | N/A |
| Completed | A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1 NCT05578872 | Anaveon AG | Phase 1 / Phase 2 |
| Active Not Recruiting | Effectiveness of Group and Individual Training in EFT for Patients in Remission From Melanoma NCT05421988 | Soul Medicine Institute | N/A |
| Active Not Recruiting | A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy NCT05732805 | Biocad | Phase 3 |
| Active Not Recruiting | Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma NCT05315258 | University of Oxford | Phase 2 |
| Unknown | Clinical Study of the Efficacy and Safety of BCD-201 and Keytruda in Subjects With Advanced Melanoma NCT05986331 | Biocad | Phase 3 |
| Terminated | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; NCT05432193 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | Phase 1 |
| Recruiting | Study of Alterations in Tumor Metabolism Associated With the Development of Immunotherapy Resistance in Melano NCT05307289 | Centre Hospitalier Universitaire de Nice | N/A |
| Recruiting | Versatile Ampification Single-Molecule Detection in Liquid Biopsy NCT05940311 | Regina Elena Cancer Institute | — |
| Unknown | Clinical vAlidation of a MobilE appLication ("ProRodinki") in the Assessment of the maLignant skIn neoplAsms NCT05402046 | MelanomaPRO, Russia | N/A |
| Completed | Zr89 + PET Companion Trial NCT05279027 | Abramson Cancer Center at Penn Medicine | EARLY_Phase 1 |
| Unknown | Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice NCT05402059 | MelanomaPRO, Russia | — |
| Unknown | MelPRO-0322 (CRISTINA Trial) [miCrobiome pRedIctS aPD1 effecTivnes In melaNoma pAtietns] NCT06299878 | Russian Academy of Medical Sciences | — |
| Completed | App Teaches Doctors to Diagnose Skin Cancer NCT05661370 | Herlev Hospital | N/A |
| Terminated | Circulating Tumour DNA guidEd Therapy for Stage IIB/C mElanoma After surgiCal resecTION NCT04901988 | The Christie NHS Foundation Trust | Phase 2 / Phase 3 |
| Active Not Recruiting | MoleGazer Development Feasibility Study NCT05015816 | Oxford University Hospitals NHS Trust | N/A |
| Completed | Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo NCT04969419 | Momentum Data | — |
| Terminated | Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma NCT04990479 | Nouscom SRL | Phase 1 |
| Terminated | This SCR-103 Protocol Will Permit Sites to Proactively Assess TAA, HLA and HPV-16 Status in Patients With Sele NCT05061940 | Repertoire Immune Medicines | — |
| Completed | OneDoc Picopulse™ for the Treatment of Melasma Among Malaysian Women NCT04834167 | Universiti Tunku Abdul Rahman | N/A |
| Completed | Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy NCT04904120 | Perspective Therapeutics | Phase 1 |
| Unknown | To Assess Immunogenicity of Coronavirus Disease 2019 (COVID-19) Vaccine in Cancer Patients Receiving Cancer Tr NCT04821570 | University of Kansas Medical Center | — |
| Completed | A Prospective Observational Study on Targeted Therapy for Unresectable or Metastatic BRAFV600E Mutant Melanoma NCT04911998 | Pierre Fabre Medicament | — |
| Completed | Melanoma Detection in Switzerland With VECTRA NCT04605822 | University Hospital, Basel, Switzerland | — |
| Unknown | Research of Pathological Imaging Diagnosis of Ocular Tumors Based on New Artificial Intelligence Algorithm NCT04695015 | Peking University | — |
| Completed | Behavioral Weight Loss Program for Cancer Survivors in Maryland NCT04534309 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Completed | AI-based Medical Device Validation for Early Melanoma Detection NCT06221397 | AI Labs Group S.L | — |
| Terminated | Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Co NCT04410445 | Nektar Therapeutics | Phase 3 |
| Completed | Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors NCT03927742 | University of Minnesota | N/A |
| Terminated | Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors NCT04301011 | Turnstone Biologics, Corp. | Phase 1 |
| Unknown | A Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Melanoma NCT04072900 | Xiangya Hospital of Central South University | Phase 1 |
| Unknown | Atypical MOLes and Melanoma Early Detection Study (MoleMed) NCT04353050 | Russian Academy of Medical Sciences | N/A |
| Withdrawn | Pilot Study of Intervention to Reduce Sunburns in Melanoma Survivors NCT03518229 | University of Minnesota | N/A |
| Completed | Phase I/IIa Study of 68GaNOTA-Anti-MMR-VHH2 for PET/CT NCT04168528 | Universitair Ziekenhuis Brussel | Phase 1 / Phase 2 |
| Terminated | Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2 NCT03233828 | Carman Giacomantonio | Phase 3 |
| Withdrawn | A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer NCT04099446 | ProgenaBiome | — |
| Completed | Improving Skin Cancer Management With Artificial Intelligence (04.17 SMARTI) NCT04040114 | Melanoma and Skin Cancer Trials Limited | N/A |
| Completed | Passive Versus Active Educational Interventions for Melanoma Recognition NCT04507048 | Azienda USL Reggio Emilia - IRCCS | N/A |
| Active Not Recruiting | SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SC NCT04079166 | Scancell Ltd | Phase 2 |
| Completed | Cryotherapy With in Situ Immunotherapy in Melanoma Metastasis NCT03949153 | University Hospital, Strasbourg, France | Phase 1 / Phase 2 |
| Completed | Aspirin as an Ultraviolet (UV) Protectant in Human Subjects at Risk for Melanoma NCT04066725 | University of Utah | Phase 2 |
| Terminated | Use of Electrical Impedance Spectroscopy (EIS) for Early Diagnosis of Skin Damage NCT04688749 | Aristotle University Of Thessaloniki | — |
| Withdrawn | Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma NCT03972046 | TriHealth Inc. | Phase 2 |
| Terminated | A Study to Evaluate Sotigalimab (APX005M) in Subjects With Unresectable or Metastatic Melanoma NCT04337931 | Apexigen America, Inc. | Phase 2 |
| Terminated | MB-CART20.1 Melanoma NCT03893019 | Miltenyi Biomedicine GmbH | EARLY_Phase 1 |
| Completed | Sample Collection Study in Patients With Suspected Melanoma Utilizing DermTech's Non-invasive Adhesive Patch B NCT04550000 | DermTech | — |
| Unknown | Biobanking and New Biomolecular Metrics NCT05906277 | Regina Elena Cancer Institute | N/A |
| Completed | Patient-led Surveillance Compared to Clinician-led Surveillance in People Treated for Localised Melanoma. NCT03581188 | University of Sydney | N/A |
| Unknown | Elucid Labs AIDA™ - Labelled Image Acquisition Protocol NCT03621462 | Elucid Labs Inc. | N/A |
| Terminated | Pembrolizumab and EDP1503 in Advanced Melanoma NCT03595683 | University of Chicago | Phase 2 |
| Completed | Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma NCT03620019 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Recruiting | Identification of Metabolic Phenotypes Associated With Melanoma Metastasis NCT06400550 | University of Texas Southwestern Medical Center | — |
| Active Not Recruiting | Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma NCT03543969 | H. Lee Moffitt Cancer Center and Research Institute | EARLY_Phase 1 |
| Terminated | Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients NCT03224208 | Fondazione Melanoma Onlus | Phase 2 |
| Completed | Therapeutic Drug Monitoring of BRAF-mutated Advanced Melanoma NCT03416933 | Institut de Cancérologie de Lorraine | N/A |
| Unknown | Predicting Response to Immunotherapy for Melanoma With Gut Microbiome and Metabolomics NCT03643289 | East and North Hertfordshire NHS Trust | — |
| Completed | Assessing Tissue Remodeling in the Skin Using SFI (Skin Fluorescence Imaging) NCT03535077 | Orlucent, Inc | — |
| Completed | Nevus Doctor Clinical Decision Support for GPs NCT03246412 | University Hospital of North Norway | N/A |
| Completed | Nivolumab in Treating Patients With Stage IIB-IIC Melanoma That Can Be Removed by Surgery NCT03405155 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery NCT02997553 | Institut de Cancérologie de Lorraine | Phase 3 |
| Completed | SPY-X: A Study to Assess the Feasibility of Using SPY Alone for Sentinel Node Localization for Melanoma or Bre NCT03294330 | Milton S. Hershey Medical Center | Phase 3 |
| Unknown | Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC NCT03291002 | CureVac | Phase 1 |
| Unknown | A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients NCT04200040 | OrienGene Biotechnology Ltd. | Phase 2 |
| Unknown | New Tumor Models in Three Dimensions and in a Human Skin Environment for Personalized Melanoma Therapy NCT03136783 | Centre Hospitalier Universitaire, Amiens | N/A |
| Completed | Reflectance Confocal Microscopy to Diagnose MM & LM NCT03508297 | Skin Care Network Ltd. | — |
| Completed | Melanoma Patients Immunized with Natural DenDritic Cells NCT02993315 | Radboud University Medical Center | Phase 3 |
| Completed | Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma NCT04062032 | University of Utah | Phase 2 |
| Completed | Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma NCT02652455 | H. Lee Moffitt Cancer Center and Research Institute | EARLY_Phase 1 |
| Completed | Skin Health Online for Melanoma: Better Risk Assessment NCT03130569 | University of New Mexico | N/A |
| Completed | Using MC1R Genotype to Impact Melanoma Risk Behavior NCT03509467 | H. Lee Moffitt Cancer Center and Research Institute | N/A |
| Recruiting | Genomic Investigation of Unusual Responders NCT03740503 | University Health Network, Toronto | — |
| Completed | Tissue and Blood Biomarkers From Patients With Stage III or Stage IV Melanoma Treated With Ipilimumab With or NCT01489423 | Eastern Cooperative Oncology Group | — |
| Completed | Pilot Trial to Evaluate the Effect of Vitamin D on Melanocyte Biomarkers NCT01477463 | Stanford University | N/A |
| Recruiting | French Clinical Datbase of Melanoma Patients (RIC-Mel) NCT03315468 | Nantes University Hospital | — |
| Completed | Biomarkers in Predicting Response to Chemotherapy in Patients With Advanced or Metastatic Melanoma Previously NCT01209299 | ECOG-ACRIN Cancer Research Group | — |
| Completed | Biomarkers in Blood Samples From Patients With Stage IV Melanoma Previously Treated With Sargramostim NCT01388569 | Eastern Cooperative Oncology Group | — |
| Completed | Study of Tumor Tissue From Patients With Melanoma Treated on Clinical Trial EST-1690 NCT00937781 | ECOG-ACRIN Cancer Research Group | — |
| Completed | Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery NCT00962845 | Rutgers, The State University of New Jersey | EARLY_Phase 1 |
| Completed | Vaccine Combining Multiple Class I Peptides and Montanide ISA 51VG With Escalating Doses of Anti-PD-1 Antibody NCT01176474 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558 NCT01176461 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | Carboplatin, Paclitaxel, and Bevacizumab With or Without Everolimus in Treating Patients With Metastatic Malig NCT00976573 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Completed | Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvov NCT00700882 | Eastern Cooperative Oncology Group | Phase 2 |
| Terminated | Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma NCT00991991 | Case Comprehensive Cancer Center | — |
| No Longer Available | Cyclophosphamide, Autologous Lymphocytes, and Aldesleukin in Treating Patients With Metastatic Melanoma NCT01005537 | Fred Hutchinson Cancer Center | — |
| Completed | Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery NCT00866840 | Rutgers, The State University of New Jersey | Phase 2 |
| Terminated | Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating P NCT00863330 | Wake Forest University Health Sciences | Phase 2 |
| Completed | Adenovirus CCL-21 Transduced MART-1/gp100/Tyrosinase/NY-ESO-1 Peptide-Pulsed Dendritic Cells Matured NCT00798629 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | Vaccine Therapy in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by S NCT00471471 | Ahmad Tarhini | Phase 1 |
| Completed | Study of Blood Samples From Patients With Malignant Melanoma, Metastatic Breast Cancer, Advanced Lung Cancer, NCT00974610 | Cancer Trials Ireland | — |
| Completed | Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Car NCT00626405 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Terminated | 0794GCC: Pentamidine in Treating Patients With Relapsed or Refractory Melanoma NCT00729807 | University of Maryland, Baltimore | Phase 2 |
| Terminated | Gene-Modified Lymphocytes, High-Dose Aldesleukin, and Vaccine Therapy in Treating Patients With Progressive or NCT00704938 | National Institutes of Health Clinical Center (CC) | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Advanced Melanoma NCT00705640 | Craig L Slingluff, Jr | Phase 1 |
| Completed | Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma NCT00658892 | Mayo Clinic | Phase 1 |
| Withdrawn | A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) NCT00661336 | Duke University | Phase 1 |
| Unknown | Study of Genes and Environment in Patients With Cancer in East Anglia, Trent, or West Midlands Regions of the NCT00757614 | Cancer Research UK | — |
| Terminated | Cryoablation or External-Beam Radiation Therapy in Treating Patients With Painful Bone Metastases NCT00540969 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Completed | Biomarkers in Patients With High-Risk Melanoma Receiving High-Dose Interferon Therapy NCT00897520 | ECOG-ACRIN Cancer Research Group | — |
| Completed | Temozolomide and Everolimus in Treating Patients With Stage IV Melanoma That Cannot be Removed by Surgery NCT00521001 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Completed | Interleukin-21 in Treating Patients With Metastatic or Recurrent Malignant Melanoma NCT00514085 | NCIC Clinical Trials Group | Phase 2 |
| Unknown | Answering Questions About Vitamin D Supplementation and Sun Exposure in Patients Who Have Undergone Surgery fo NCT00672321 | Leeds Cancer Centre at St. James's University Hospital | — |
| Completed | Temozolomide and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery NCT00568048 | Swiss Cancer Institute | Phase 2 |
| Completed | Biomarkers That Predict Response to High-Dose Aldesleukin in Metastatic Kidney Cancer or Metastatic Melanoma NCT00617799 | University of Nebraska | — |
| Terminated | Conformal Radiation Therapy in Treating Patients With Metastatic Cancer Outside the Brain NCT00550654 | National Institutes of Health Clinical Center (CC) | Phase 2 |
| Unknown | Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, NCT00553683 | Rutgers, The State University of New Jersey | Phase 1 / Phase 2 |
| Completed | Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or L NCT00565968 | Duke University | Phase 1 |
| Completed | Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma NCT00512889 | Dana-Farber Cancer Institute | Phase 1 |
| Completed | Sulindac and Epirubicin in Treating Patients With Metastatic Malignant Melanoma NCT00755976 | Cancer Trials Ireland | Phase 2 |
| Completed | BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors NCT00526149 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Unknown | Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma NCT00811759 | Gustave Roussy, Cancer Campus, Grand Paris | Phase 1 / Phase 2 |
| Completed | Biomarkers to Predict Response to Interferon Therapy in Patients With Melanoma NCT00897546 | ECOG-ACRIN Cancer Research Group | — |
| Terminated | Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer NCT00492440 | Cytheris SA | Phase 1 |
| Unknown | Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma NCT00538005 | San Diego Pacific Oncology & Hematology Associates | Phase 1 / Phase 2 |
| Unknown | Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma NCT00492505 | San Diego Pacific Oncology & Hematology Associates | Phase 2 |
| Completed | Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation NCT00471133 | Ichor Medical Systems Incorporated | Phase 1 |
| Completed | Vaccine Therapy and GM-CSF With or Without Low-Dose Aldesleukin in Treating Patients With Stage II, Stage III, NCT00470015 | Mayo Clinic | Phase 1 |
| Completed | Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma NCT00462982 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors NCT00667641 | University of Medicine and Dentistry of New Jersey | Phase 1 |
| Terminated | Riluzole in Treating Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery NCT00667901 | University of Medicine and Dentistry of New Jersey | Phase 1 |
| Completed | Ticilimumab (CP-675,206) in Treating Patients With Stage IIIC or Stage IV Melanoma NCT00471887 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Unknown | Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy NCT00897481 | Leeds Cancer Centre at St. James's University Hospital | — |
| Completed | Vaccine Therapy and GM-CSF in Treating Patients With Recurrent or Metastatic Melanoma NCT00436930 | Hoag Memorial Hospital Presbyterian | Phase 2 |
| Completed | Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic Cancer NCT00436410 | National Institutes of Health Clinical Center (CC) | EARLY_Phase 1 |
| Unknown | Bioelectric Field Imaging in Diagnosing Melanoma and Other Skin Cancers in Patients With Skin Lesions NCT00391300 | Eastern Virginia Medical School | Phase 1 |
| Completed | Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery NCT00404235 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma NCT00398073 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma NCT00390338 | Pawel Kalinski | Phase 1 |
| Terminated | Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma NCT00568451 | Mayo Clinic | Phase 2 |
| Withdrawn | Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma NCT00357461 | Bristol-Myers Squibb | Phase 2 |
| Completed | Vaccine Therapy and Resiquimod in Treating Patients With Stage II, Stage III, or Stage IV Melanoma That Has Be NCT00470379 | Mayo Clinic | EARLY_Phase 1 |
| Completed | Investigation of a Behavioral Substitute for Sunbathing NCT00403377 | University of Massachusetts, Worcester | Phase 1 / Phase 2 |
| Completed | Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney NCT00316901 | National Institutes of Health Clinical Center (CC) | Phase 2 |
| Completed | Imiquimod and Laser Therapy With or Without a Green Dye in Treating Patients With Stage III or Stage IV Melano NCT00453050 | University of Oklahoma | Phase 1 |
| Unknown | Comparing Follow-Up Schedules in Patients With Newly Diagnosed Stage IB or Stage II Melanoma NCT01018004 | University Medical Center Groningen | — |
| Completed | Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable NCT00324727 | Delcath Systems Inc. | Phase 3 |
| Completed | Vatalanib in Treating Patients With Metastatic Cutaneous Melanoma That Cannot be Removed by Surgery NCT00563823 | Cambridge University Hospitals NHS Foundation Trust | Phase 2 |
| Completed | Dendritic Cell Vaccination During Lymphoid Reconstruction NCT00313508 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | Azacitidine and Interferon Alfa in Treating Patients With Metastatic Melanoma NCT00398450 | University of California, San Diego | Phase 1 |
| Completed | Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal NCT00445965 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By NCT00295958 | National Institutes of Health Clinical Center (CC) | Phase 2 |
| Completed | Radiofrequency Therapy-Induced Endogenous Heat-Shock Proteins With or Without Radiofrequency Ablation or Cryot NCT00568763 | Mayo Clinic | Phase 1 |
| Completed | Genistein and Interleukin-2 in Treating Patients With Metastatic Melanoma or Kidney Cancer NCT00276835 | Northwestern University | EARLY_Phase 1 |
| Completed | Studying Genes to Identify Melanoma in Patients in Iceland and Their Family Members NCT00346008 | Iceland Genomics Corporation | — |
| Completed | Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients W NCT00324623 | Prof. Serge Leyvraz | Phase 1 |
| Terminated | Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating P NCT00138229 | National Institutes of Health Clinical Center (CC) | Phase 2 |
| Suspended | Paclitaxel and GM-CSF in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surge NCT00278122 | University of Virginia | Phase 2 |
| Unknown | Vaccine Therapy in Treating Patients With Malignant Melanoma NCT00128583 | CancerVax Corporation | Phase 2 |
| Completed | S0508: Thalidomide and Temozolomide in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surg NCT00104988 | SWOG Cancer Research Network | Phase 2 |
| Completed | Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Met NCT00071981 | Eastern Cooperative Oncology Group | Phase 2 |
| Completed | Hu14.18-Interleukin-2 Fusion Protein in Treating Patients With Advanced Melanoma NCT00109863 | University of Wisconsin, Madison | Phase 2 |
| Completed | Everolimus in Treating Patients With Stage IV Melanoma NCT00098553 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Unknown | Vaccine Therapy in Treating Patients With Stage IV Melanoma NCT00126685 | Dermatologische Klinik MIT Poliklinik-Universitaetsklinikum Erlangen | Phase 1 / Phase 2 |
| Completed | 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma NCT00104897 | Cancer Research UK | Phase 2 |
| Completed | Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Who Have Undergone Surgery for Stage II, NCT00118274 | Craig L Slingluff, Jr | Phase 1 / Phase 2 |
| Completed | Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma NCT00602576 | Abramson Cancer Center at Penn Medicine | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Unresected Stage III or Stage IV Melanoma NCT00107159 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Completed | Vaccine Therapy With or Without Imiquimod in Treating Patients Who Have Undergone Surgery for Stage II, Stage NCT00118313 | Craig L Slingluff, Jr | Phase 1 |
| Completed | ABT-510 in Treating Patients With Metastatic Melanoma NCT00602199 | Mayo Clinic | Phase 2 |
| Completed | SB-715992 in Treating Patients With Metastatic or Recurrent Malignant Melanoma NCT00095953 | NCIC Clinical Trials Group | Phase 2 |
| Completed | Universal Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)-Producing and CD40L Expressing Bystander C NCT00101166 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma NCT00104845 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autolog NCT00096382 | National Institutes of Health Clinical Center (CC) | Phase 2 |
| Completed | Interleukin-7 and Vaccine Therapy in Treating Patients With Metastatic Melanoma NCT00091338 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Cyclophosphamide and Fludarabine Followed by Vaccine Therapy, Gene-Modified White Blood Cell Infusions, and Al NCT00091104 | National Institutes of Health Clinical Center (CC) | Phase 1 |
| Completed | Fludarabine Followed by Vaccine Therapy and White Blood Cell Infusions in Treating Patients With Unresectable NCT00091143 | Providence Cancer Center, Earle A. Chiles Research Institute | Phase 1 |
| Unknown | Computer-Based Continuing Education for Doctors in Examination and Counseling of Patients on Skin Cancer or We NCT00295906 | Rhode Island Hospital | N/A |
| Completed | Pegylated Arginine Deiminase in Treating Patients With Metastatic Melanoma That Cannot Be Removed by Surgery NCT00450372 | University of Miami | Phase 2 |
| Completed | Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melan NCT00084656 | Bristol-Myers Squibb | Phase 2 |
| Unknown | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery NCT00086866 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Completed | Gene-Modified White Blood Cells Followed By Interleukin-2 and Vaccine Therapy in Treating Patients With Metast NCT00085462 | National Institutes of Health Clinical Center (CC) | Phase 1 |
| Terminated | Boron Neutron Capture Therapy Using Boronophenylalanine-Fructose Complex in Treating Patients With Metastatic NCT00085059 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Completed | CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patie NCT00090896 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Completed | Denileukin Diftitox in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer NCT00082914 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Me NCT00077532 | National Institutes of Health Clinical Center (CC) | Phase 2 |
| Unknown | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma NCT00085397 | Dana-Farber Cancer Institute | Phase 2 |
| Withdrawn | Interleukin-2 and Sargramostim After Chemotherapy in Treating Patients With Stage III or Stage IV Melanoma NCT00085579 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma NCT00085488 | Dartmouth-Hitchcock Medical Center | Phase 1 |
| Completed | ABI-007 in Treating Patients With Inoperable Locally Recurrent or Metastatic Melanoma NCT00081042 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Completed | Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma NCT00085423 | Dartmouth-Hitchcock Medical Center | Phase 2 |
| Completed | PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma NCT00049530 | Eastern Cooperative Oncology Group | Phase 2 |
| Completed | Lymphocyte-Depleting Nonmyeloablative Preparative Chemotherapy Followed By Autologous Lymphocyte Infusion, Pep NCT00079144 | National Cancer Institute (NCI) | Phase 2 |
| Completed | PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma NCT00073892 | Cellxpert Biotechnology Corp. | Phase 1 / Phase 2 |
| Terminated | Temozolomide and Radiation Therapy in Treating Patients With Stage IV Malignant Melanoma With Measurable and U NCT00068666 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Metastatic Melanoma NCT00334776 | University of Southern California | Phase 2 |
| Completed | Immunization With gp100 Protein Vaccine in Treating Patients With Metastatic Melanoma NCT00072085 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vaccine Therapy With or Without Sargramostim in Treating Patients With Stage IIB, Stage IIC, Stage III, or Sta NCT00089193 | Craig L Slingluff, Jr | Phase 2 |
| Completed | Dacarbazine and/or Cisplatin Compared With Complete Metastasectomy in Treating Patients With Stage IV Melanoma NCT00072124 | National Cancer Institute (NCI) | Phase 3 |
| Terminated | Fotemustine in Treating Patients With Metastatic Melanoma NCT00560118 | Institut du Cancer de Montpellier - Val d'Aurelle | Phase 2 |
| Unknown | Oblimersen and Dacarbazine in Treating Patients With Advanced Malignant Melanoma That Has Responded to Treatme NCT00070343 | Jonsson Comprehensive Cancer Center | N/A |
| Completed | Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma NCT00089219 | University of Virginia | Phase 1 / Phase 2 |
| Completed | Temozolomide, Thalidomide, and Lomustine in Treating Patients With Unresectable Stage III or Stage IV Melanoma NCT00072345 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Stage IV Cutaneous Melanoma NCT00074230 | University Hospital Erlangen | Phase 1 / Phase 2 |
| Completed | Perifosine in Treating Patients With Metastatic or Recurrent Malignant Melanoma NCT00053781 | NCIC Clinical Trials Group | Phase 2 |
| Completed | Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Tre NCT00062036 | National Institutes of Health Clinical Center (CC) | Phase 1 / Phase 2 |
| Completed | Fludarabine Followed By Adoptive Immunotherapy in Treating Patients With Stage IV Melanoma NCT00317759 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Monoclonal Antibody Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma NCT00058279 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Vaccine Therapy and Interleukin-2 in Treating Patients With Metastatic Melanoma NCT00054535 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma NCT00053391 | University Hospital Erlangen | Phase 1 / Phase 2 |
| Unknown | Melanoma Vaccine in Treating Patients With Stage III Melanoma After Surgery to Remove Lymph Nodes NCT01082198 | Maria Sklodowska-Curie National Research Institute of Oncology | Phase 1 / Phase 2 |
| Completed | Biological Therapy in Treating Patients With Metastatic Melanoma NCT00045149 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma NCT00056134 | University Hospital Erlangen | Phase 1 / Phase 2 |
| Completed | Diagnostic Study to Predict the Risk of Developing Metastatic Cancer in Patients With Stage I or Stage II Mela NCT00049010 | Alliance for Clinical Trials in Oncology | N/A |
| Unknown | Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic NCT00039234 | Maxim Pharmaceuticals | Phase 3 |
| Completed | Vaccine Therapy in Treating Patients With Stage IV Melanoma NCT00042783 | SWOG Cancer Research Network | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery NCT00089206 | University of Virginia | Phase 2 |
| Completed | Boron Neutron Capture Therapy in Treating Patients With Glioblastoma Multiforme or Melanoma Metastatic to the NCT00039572 | Beth Israel Deaconess Medical Center | Phase 1 / Phase 2 |
| Completed | Inhaled Sargramostim in Treating Patients With Melanoma Metastatic to the Lung NCT00017121 | Alliance for Clinical Trials in Oncology | Phase 1 |
| Completed | Boron Neutron Capture Therapy in Treating Patients With Melanoma NCT00059800 | Beth Israel Deaconess Medical Center | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Stage IV or Recurrent Malignant Melanoma NCT00039325 | Jonsson Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Completed | Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Me NCT00031733 | University of Southern California | Phase 2 |
| Completed | Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma NCT00032045 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Stage IV Melanoma NCT00033228 | Mannkind Corporation | Phase 1 / Phase 2 |
| Completed | Biological Therapy in Treating Patients With Metastatic Melanoma NCT00045357 | Fred Hutchinson Cancer Center | Phase 1 |
| Completed | Interferon Alfa and Thalidomide in Treating Patients With Stage IV Melanoma NCT00026520 | SWOG Cancer Research Network | Phase 2 |
| Unknown | Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma NCT00037037 | Herbert Irving Comprehensive Cancer Center | Phase 1 |
| Completed | Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been NCT00025181 | University of Southern California | Phase 1 |
| Completed | Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors NCT00003750 | Children's Oncology Group | Phase 1 |
| Unknown | Vaccine Therapy in Treating Patients With Metastatic Melanoma NCT00022568 | Herbert Irving Comprehensive Cancer Center | Phase 1 |
| Completed | Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma That Has Not Respo NCT00022438 | National Cancer Institute (NCI) | Phase 2 |
| Completed | CCI-779 in Treating Patients With Metastatic Melanoma NCT00022464 | City of Hope Medical Center | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Metastatic Cancer NCT00021164 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma NCT00027742 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Vaccine Therapy in Treating Patients With Metastatic Melanoma NCT00017355 | Baylor Health Care System | Phase 1 |
| Terminated | Temozolomide With or Without Radiation Therapy to the Brain in Treating Patients With Stage IV Melanoma That I NCT00020839 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
| Completed | Thalidomide and SU5416 in Treating Patients With Metastatic Melanoma NCT00017316 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Biological Therapy in Treating Patients With Metastatic Melanoma or Metastatic Kidney Cancer NCT00020540 | National Cancer Institute (NCI) | Phase 1 |
| Completed | E7070 in Treating Patients With Stage IV Melanoma NCT00014625 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 2 |
| Completed | PEG-Interferon Alfa-2b and Thalidomide in Treating Patients With Recurrent or Metastatic Melanoma NCT00238329 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Refractory Metastatic Melanoma NCT00020397 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Vaccine Therapy in Treating Patients Who Have Stage II, Stage III, or Stage IV Melanoma NCT00010309 | Genzyme, a Sanofi Company | Phase 1 / Phase 2 |
| Unknown | Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma NCT00016055 | St. Luke's Medical Center | Phase 1 |
| Completed | Photodynamic Therapy in Treating Patients With Stage III or Stage IV Melanoma NCT00007969 | QLT Inc. | Phase 1 / Phase 2 |
| Completed | Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer NCT00006022 | Virginia Commonwealth University | Phase 1 |
| Completed | Study of Aerosolized Sargramostim in Treating Patients With Melanoma Metastatic to the Lung NCT00005610 | Alliance for Clinical Trials in Oncology | Phase 2 |
| Completed | Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma NCT00006385 | Eastern Cooperative Oncology Group | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Melanoma NCT00020358 | National Cancer Institute (NCI) | Phase 2 |
| Completed | S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma NCT00006237 | SWOG Cancer Research Network | Phase 3 |
| Completed | Flavopiridol in Treating Patients With Metastatic Malignant Melanoma NCT00005971 | NCIC Clinical Trials Group | Phase 2 |
| Unknown | Study of Families With Melanoma NCT00445783 | Leeds Cancer Centre at St. James's University Hospital | — |
| Completed | Vaccine Therapy in Treating Patients With Stage IV Melanoma NCT00023647 | Mannkind Corporation | Phase 1 |
| Completed | Dacarbazine With or Without Oblimersen (G3139) in Treating Patients With Advanced Malignant Melanoma NCT00016263 | Genta Incorporated | Phase 3 |
| Completed | Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma NCT00012064 | Lisata Therapeutics, Inc. | Phase 1 / Phase 2 |
| Unknown | Interferon Alfa Following Surgery in Treating Patients With Stage III Melanoma NCT00006249 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
| Completed | O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanom NCT00005961 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Bleomycin With or Without Electroporation Therapy in Treating Patients With Stage III or Stage IV Melanoma NCT00006035 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Terminated | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma NCT00005841 | University of Southern California | Phase 1 |
| Completed | Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma NCT00005057 | National Human Genome Research Institute (NHGRI) | Phase 1 |
| Completed | Interleukin-12 and Interferon Alfa in Treating Patients With Metastatic Kidney Cancer or Malignant Melanoma NCT00004244 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors NCT00014456 | Dartmouth-Hitchcock Medical Center | Phase 1 |
| Completed | Gene Therapy in Treating Patients With Metastatic Melanoma NCT00005943 | University of Colorado, Denver | Phase 1 |
| Withdrawn | High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma NCT00447356 | Hackensack Meridian Health | Phase 3 |
| Completed | Combination Chemotherapy, Total-Body Irradiation, Peripheral Stem Cell Transplantation, and Lymphocyte Infusio NCT00006233 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Chemotherapy Followed by Biological Therapy in Treating Patients With Stage IV Melanoma That Cannot be Treated NCT00014092 | Saint Francis Hospital | Phase 2 |
| Unknown | Vaccine Therapy in Treating Patients With Primary Stage II Melanoma NCT00005052 | European Organisation for Research and Treatment of Cancer - EORTC | Phase 3 |
| Completed | Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma NCT00005815 | Memorial Sloan Kettering Cancer Center | Phase 1 / Phase 2 |
| Completed | Irofulven in Treating Patients With Stage IV Melanoma NCT00005968 | University of Colorado, Denver | Phase 2 |
| Completed | Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma NCT00019669 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Unresectable Metastatic Melanoma NCT00004148 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis NCT00004196 | University of Alabama at Birmingham | Phase 3 |
| Completed | Vaccine Therapy in Treating Patients With Metastatic Melanoma NCT00019994 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular NCT00006126 | Northwestern University | Phase 1 |
| Completed | Isolated Limb Infusion of Chemotherapy in Treating Patients With Melanoma or Soft Tissue Sarcoma of the Arm or NCT00004250 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Terminated | S9903: Whole Brain Radiotherapy Followed By Stereotactic Radiosurgery for Limited Malignant Melanoma Brain Met NCT00003911 | SWOG Cancer Research Network | Phase 2 |
| Completed | Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer NCT00004065 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Vaccine Therapy in Treating Patients With Metastatic Melanoma NCT00019734 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma NCT00006113 | University of Southern California | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma NCT00005633 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Completed | Vaccine Therapy With gp100 and/or Sargramostim in Treating Patients With Malignant Melanoma NCT00003897 | University of Wisconsin, Madison | Phase 1 |
| Completed | S9804: Vinorelbine in Treating Patients With Stage IV Melanoma NCT00003828 | SWOG Cancer Research Network | Phase 2 |
| Completed | Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma NCT00019721 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Stage IV Melanoma NCT00003665 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors NCT00004016 | University of Rochester | Phase 1 |
| Completed | Vaccine Therapy in Treating Patients With Metastatic Melanoma NCT00003792 | Baylor Health Care System | Phase 1 |
| Completed | Interferon Alfa-2b With or Without Radiation Therapy in Treating Patients With Melanoma That Has Metastasized NCT00003444 | Eastern Cooperative Oncology Group | Phase 3 |
| Active Not Recruiting | High-Dose Interferon Alfa in Treating Patients With Stage II or Stage III Melanoma NCT00003641 | ECOG-ACRIN Cancer Research Group | Phase 3 |